🟢 80/100

This product is generally safe

  • Vitamin D: 0.125mg is 1.2× the Tolerable Upper Intake Level (0.1mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Vitamin D: 0.125mg is 1.2× the Tolerable Upper Intake Level (0.1mg)

Label Data

1 Capsule(s) Serving Size
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

5000 IU (1250% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.2× (UL: 0.1 mg) 📚 604 studies (Tier A: 16, B: 251)
RDA 0.015mg This product: 0.125mg UL 0.1mg
550 mcg (690% DV)
📊 4.6× RDA — above typical dose 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.55mg

Other Ingredients

Microcrystalline Cellulose L-Leucine

Label Claims — Verification

All Other
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

Recommended Use: As a dietary supplement, take one capsule per day with a meal, or as directed by your health care practitioner.

⚠️ Warnings & Precautions

KEEP OUT OF REACH OF CHILDREN.

Warning: Consult your health care practitioner before taking this product if you are taking Coumadin, warfarin or other anticoagulant medications.

🧪 Formulation Notes

Does not contain gluten.

Additional Information

Guaranteed GMP COMPLIANT Products

STORE IN A COOL, DRY PLACE.

MADE WITH NON-GMO INGREDIENTS

Notice: Color, size or shape may appear different between lots.

VDS180-2

For Professional Use Only

Product Details

UPC / SKU 8 79452 00299 9
DSLD Entry Date 2013-09-25
Product Type Vitamin
Form Capsule
DSLD ID 23407
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →